HEAT BIOLOGICS INC (HTBX)

US42237K4094 - Common Stock

2.38  +0.01 (+0.42%)

Fundamental Rating

2

Overall HTBX gets a fundamental rating of 2 out of 10. We evaluated HTBX against 588 industry peers in the Biotechnology industry. HTBX may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, HTBX is valued expensive at the moment.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

HTBX had negative earnings in the past year.
In the past 5 years HTBX always reported negative net income.
In the past 5 years HTBX always reported negative operating cash flow.

1.2 Ratios

Industry RankSector Rank
ROA -28.99%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

HTBX does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) -1658.78%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

HTBX has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, HTBX has a worse debt to assets ratio.

2.2 Solvency

An Altman-Z score of 2.71 indicates that HTBX is not a great score, but indicates only limited risk for bankruptcy at the moment.
A Debt/Equity ratio of 0.00 indicates that HTBX is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.71
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

HTBX has a Current Ratio of 21.04. This indicates that HTBX is financially healthy and has no problem in meeting its short term obligations.
HTBX has a Quick Ratio of 21.04. This indicates that HTBX is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 21.04
Quick Ratio 21.04

More info and screens

5

3. Growth

3.1 Past

HTBX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.62%, which is quite good.
HTBX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -28.09%.
The Revenue has been growing by 44.10% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)9.62%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-2600%
Revenue 1Y (TTM)-28.09%
Revenue growth 3Y-28.54%
Revenue growth 5Y44.1%
Revenue growth Q2Q2.18%

3.2 Future

Based on estimates for the next years, HTBX will show a decrease in Earnings Per Share. The EPS will decrease by -0.56% on average per year.
The Revenue is expected to grow by 136.46% on average over the next years. This is a very strong growth
EPS Next Y-23.7%
EPS Next 2Y-3.24%
EPS Next 3Y10.19%
EPS Next 5Y-0.56%
Revenue Next Year128.57%
Revenue Next 2Y55.11%
Revenue Next 3Y129.35%
Revenue Next 5Y136.46%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

HTBX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HTBX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.04

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.24%
EPS Next 3Y10.19%

More info and screens

0

5. Dividend

5.1 Amount

HTBX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HEAT BIOLOGICS INC

NYSEARCA:HTBX (5/2/2022, 7:04:01 PM)

2.38

+0.01 (+0.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap61.05M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.99%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) -1658.78%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 21.04
Quick Ratio 21.04
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)9.62%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-23.7%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-28.09%
Revenue growth 3Y-28.54%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y